Valerian

Valerian produces CNS depression through GABAergic mechanisms. Combined with opioid CNS depression, there is additive impairment of psychomotor function and potential respiratory depression. No direct PK interaction documented, but the pharmacodynamic additive effect is clinically meaningful, especially at higher opioid doses.

Patients should be advised not to take Valerian alongside opioid medications without clinician guidance. Monitor for excessive sedation, respiratory depression, and falls. Avoid in outpatients operating machinery. Particularly important in opioid-naive patients.

Valerian potentiates the CNS-depressant effects of anesthetic agents through additive GABAergic activity. Case reports and animal studies suggest prolonged anesthetic recovery times. Additionally, abrupt discontinuation before surgery may cause withdrawal-like effects (anxiety, cardiac complications) in patients with long-term use.

Instruct patients to discontinue Valerian at least 1-2 weeks before elective surgery. Inform the anesthetic team if a patient is on Valerian. If abrupt discontinuation is not feasible, discuss with the anesthesiologist. Do not restart immediately post-operatively.

Valerian exerts sedative and GABAergic CNS-depressant effects which may pharmacodynamically oppose the alerting and stimulant properties of methylphenidate and amphetamine-class medications used for ADHD and narcolepsy. The net clinical effect may be reduced therapeutic efficacy of the stimulant, though direct evidence is limited.

Advise ADHD patients on stimulant medication that Valerian may blunt therapeutic effects, particularly alerting and cognitive-enhancing properties. If using Valerian for sleep induction (at night), this is less likely to interfere with daytime stimulant activity. Timing of doses is important.

Valerenic acid and isovalerenic acid in Valerian act as partial agonists at GABA-A receptors and inhibit GABA transaminase, increasing GABAergic tone. This mechanism is additive with benzodiazepine-induced GABA-A potentiation. A published case report documents excessive sedation, dizziness, and muscular fatigue in a patient self-medicating with Valerian and Passionflower while on lorazepam.

Advise patients on benzodiazepines not to add Valerian without medical supervision. If co-used, start with the lowest effective Valerian dose and monitor for excessive sedation, falls risk, and respiratory depression. Avoid in elderly patients.

Valerian GABAergic activity (GABA-A receptor agonism and GABA reuptake inhibition) potentiates barbiturate-induced CNS depression through additive mechanisms at the GABA-A receptor complex. Animal studies demonstrate enhanced pentobarbital-induced sleep time with valerian pretreatment.

Avoid concurrent use, particularly in patients on phenobarbital for seizure control. If used together, monitor for excessive sedation, respiratory depression, and cognitive impairment. This combination is particularly risky in elderly patients and those with respiratory conditions.

Valerian root (valerenic acid, isovaleric acid, GABA precursors) potentiates GABA-A receptor-mediated CNS inhibition and modulates serotonin signalling. Alcohol similarly enhances GABA-A receptor activity and inhibits NMDA receptors. Combined use produces synergistic CNS depression: amplified sedation, cognitive impairment, impaired psychomotor function, reduced reaction time, and increased respiratory depression risk.

Advise patients to avoid alcohol consumption when taking valerian root supplements, particularly when driving or operating machinery. Even moderate alcohol intake may produce disproportionate sedation when combined with therapeutic valerian doses. Counsel perioperative patients to disclose valerian use, and allow adequate washout before procedures involving CNS depressants.

Valerian modulates GABA-A receptor function and serotonin metabolism via valerenic acid-mediated allosteric GABA-A modulation. Tricyclic antidepressants (TCAs) possess inherent CNS sedative, antihistaminergic, and anticholinergic properties. Combined use produces additive CNS depression, sedation, and anticholinergic burden — particularly dangerous in elderly patients with higher anticholinergic sensitivity.

Caution warranted when valerian is co-administered with TCAs. Monitor for excessive sedation, cognitive impairment, confusion, dry mouth, urinary retention, and falls — especially in elderly patients. If insomnia management is needed in patients on TCAs, consider non-pharmacological approaches before adding valerian.

Valerian root exerts anticonvulsant effects through GABA-A receptor positive modulation and may have additive pharmacodynamic effects with anticonvulsant medications. While clinical interaction evidence is limited, additive CNS sedation is physiologically plausible. In vitro studies also suggest weak CYP2C19 effects that could theoretically alter valproate or phenytoin metabolism.

Monitor seizure control and CNS side effects when valerian is added to anticonvulsant regimens. Counsel patients not to self-medicate insomnia with valerian without informing their neurologist. Maintain therapeutic drug monitoring for anticonvulsants (phenytoin, valproate, carbamazepine) if valerian is used concurrently.

Z-drugs act at the benzodiazepine-binding site of GABA-A receptors to produce sedation and hypnosis. Valerian valerenic acid and isovalerenic acid are positive allosteric modulators at GABA-A receptors, enhancing chloride conductance. Combined use produces additive GABAergic CNS depression, potentially resulting in excessive sedation, psychomotor impairment, and rebound insomnia risk upon discontinuation.

Avoid combining valerian with Z-drugs unless under medical supervision. Patients who self-medicate insomnia with both zolpidem and valerian are at risk of compounded sedation, morning hangover effect, and increased fall risk in elderly patients. Advise patients to choose one approach. If switching from Z-drugs to valerian, gradual tapering of the pharmaceutical agent is recommended.

Some commercially available valerian preparations are formulated as alcohol-based tinctures or contain significant ethanol as the extraction solvent. Concomitant ingestion of alcohol-containing preparations with metronidazole or disulfiram may precipitate a disulfiram-like reaction (flushing, nausea, vomiting, tachycardia, hypotension) due to aldehyde dehydrogenase inhibition.

When prescribing metronidazole or disulfiram, specifically ask about valerian tincture use (not just tablet/capsule forms). Advise patients to switch to alcohol-free valerian formulations (standardised aqueous extract capsules) during any course of these medications. Disulfiram interactions can be severe; this is a preventable interaction with simple product substitution.